Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Sol-Gel Technologies, Ltd. acquired topically applied patidegib, a hedgehog-signaling pathway blocker for the treatment of Gorlin syndrome, from BridgeBio Pharma, Inc. affiliate PellePharm, Inc. on 27 January. Headquartered in Israel, Sol-Gel is paying $4
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?